Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Obtains China Rights to Myeloma Candidate in $120 Million Deal

publication date: Nov 30, 2017

I-Mab Biopharma, a Tianjin company, in-licensed greater China rights to an anti-CD38 antibody discovered by Germany's MorphoSys AG. The deal could be worth up to $120 million. MorphoSys is testing the candidate in a Phase I/IIa trial in patients with relapsed/refractory multiple myeloma. I-Mab was formed earlier this year when Third Venture Biopharma merged with Tasgen and raised $150 million in capital from C-Bridge/I-Bridge Capital and Tasly Pharma. I-Mab intends to develop innovative biologics for immuno-oncology and autoimmune diseases. More details....

Stock Symbol: (FSE: MOR)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.